Skip directly to site content Skip directly to search
U.S. flag An official website of the United States government

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

NOTE: A surveillance case definition is a set of uniform criteria used to define a disease for public health surveillance. Surveillance case definitions enable public health officials to classify and count cases consistently across reporting jurisdictions. Surveillance case definitions are not intended to be used by healthcare providers for making a clinical diagnosis or determining how to meet an individual patient’s health needs.

CSTE Position Statement(s)

  • 22-ID-05


  • Candida auris, clinical
  • Candida auris, screening


Candida auris (C. auris) is an emerging multidrug-resistant yeast that can colonize the skin and cause invasive infections. It can spread readily between patients in healthcare facilities, causing numerous outbreaks that have been difficult to control. Containment of C. auris spread largely depends on timely detection and implementation of appropriate infection prevention and control measures (1).

Laboratory Criteria

Confirmatory laboratory evidence:

  • Detection of C. auris in a specimen from a swab obtained for the purpose of colonization screening using either culture or validated culture-independent test (e.g., nucleic acid amplification test [NAAT]), OR
  • Detection of C. auris in a clinical specimen obtained during the normal course of care for diagnostic or treatment purposes using either culture or a validated culture-independent test (e.g., NAAT)

Note: The categorical labels used here to stratify laboratory evidence are intended to support the standardization of case classifications for public health surveillance. The categorical labels should not be used to interpret the utility or validity of any laboratory test methodology.

Criteria to Distinguish a New Case from an Existing Case

A patient who is colonized or infected with C. auris is considered colonized indefinitely. The following provides guidance for health departments to distinguish a new case for patients who test positive for C. auris in either a screening swab (i.e., screening case) or in a clinical specimen (i.e., clinical case).

  • For screening cases, count patient only once as a screening case; do not count if patient has been previously identified as a clinical or screening case. A person with a screening case can be later categorized as a clinical case (e.g., patient with positive screening swab who later develops bloodstream infection would be counted in both categories).
  • For clinical cases, count patient only once as a clinical case, even if the patient has already been counted separately as a screening case. A person with a clinical case should not be counted as a screening case thereafter because all clinical cases are considered to also be colonized with C. auris (e.g., patient with clinical C. auris specimen who later has positive screening swab is not counted as a screening case).

Subtype(s) Case Definition


  1. Caceres DH, Forsberg K, Welsh RM, et al. Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings. J Fungi (Basel). 2019;5(4):111. Published 2019 Nov 28. doi:10.3390/jof5040111

Related Case Definition(s)